Obesity is one of the main risk factors for type 2 diabetes (T2D), representing a major
worldwide health crisis. Modest weight-loss (≥ 5% but< 10%) can minimize and reduce …

To achieve good metabolic control in diabetes and keep long term, a combination of
changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal …

Objective: To formulate clinical practice guidelines for the pharmacological management of
obesity. Participants: An Endocrine Society-appointed Task Force of experts, a …

The global prevalence of obesity is increasing rapidly with an exponential rise in incidence
of type 2 diabetes mellitus in recent years.'Diabesity', the term coined to show the strong …

Introduction: Postprandial hyperglycemia (PPHG) contributes to micro-and macro-vascular
complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due …

Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
compared with metformin as monotherapy, or with other commonly used hypoglycaemic …

BACKGROUND: Considerable clinical data on the treatment of type 2 diabetes with incretin-
based therapies (glucagon-like peptide 1 receptor agonists [GLP-1RAs] and dipeptidyl …

Introduction When first line therapy with metformin is insufficient for patients with type 2
diabetes (T2D), the optimal adjunctive therapy is unclear. We assessed the efficacy and …

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are oral antidiabetic agents that hold the potential
of slowing the progress of type 2 diabetes mellitus. Their long‐term safety is still a subject of …

Background Chronic non-communicable diseases (CNCD) represent a major cause of
morbidity and mortality. Type 2 diabetes mellitus (T2DM) is one of the most prevalent CNCD …